Stockscreener 앱 받기
507.56
0.04%
0.19
시간 외 거래:
507.56
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat
Madrigal Uses Equity Awards to Recruit 10 Employees - MyChesCo
Madrigal Pharmaceuticals Inc (0JXI) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan - Kalkine Media
Madrigal Pharmaceuticals appoints J&J executive to board - Investing.com
Form 8K Madrigal Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Canada
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors - The Manila Times
Madrigal Pharmaceuticals appoints J&J executive to board By Investing.com - Investing.com India
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Royal Bank of Canada - MarketBeat
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Precision Trading with Madrigal Pharmaceuticals Inc. (MDGL) Risk Zones - Stock Traders Daily
Madrigal at Canaccord Genuity growth conference: Rezdiffra gains pace By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion - webull.com
Madrigal Sets Investor Presentation as MASH Strategy Advances - MyChesCo
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Promising 32.94% Upside in the Biotech Sector - DirectorsTalk Interviews
Assenagon Asset Management S.A. Buys 108,181 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Bank of America Corp DE Sells 226,498 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Madrigal’s Aug. 11 Investor Presentation Will Be Webcast Live - Stock Titan
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach (NASDAQ:MDGL) - Seeking Alpha
California State Teachers Retirement System Buys 3,039 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Outperform at Wolfe Research - MarketBeat
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 46% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
Principal Financial Group Inc. Sells 6,022 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Groupama Asset Managment Buys 4,618 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth - Yahoo Finance
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Stronger Rezdiffra Momentum and New Patents Altering The Investment Case For Madrigal Pharmaceuticals (MDGL)? - simplywall.st
Madrigal Pharmaceuticals Shares Slide as Investors Reassess a High Earnings Bar - Quiver Quantitative
Canaccord Genuity Remains a Buy on Madrigal Pharmaceuticals (MDGL) - theglobeandmail.com
Madrigal: Q2 Earnings Snapshot - WKYC
Q2 2026 Madrigal Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Madrigal earnings in focus as Rezdiffra launch accelerates - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Raised to "Strong-Buy" at Wells Fargo & Company - MarketBeat
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MDGL Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Madrigal Pharmaceuticals (MDGL) Stock Analysis: Exploring a 24.82% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Paulson & CO. Inc. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. Revenue Breakdown – XETR:YDO1 - TradingView
California Public Employees Retirement System Has $12.14 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Madrigal Pharmaceuticals (MDGL) to Release Earnings on Thursday - MarketBeat
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553 - Moomoo
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares By Investing.com - Investing.com Australia
UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669 - Moomoo
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal New Hires Receive Options With $550.25 Exercise Price - Stock Titan
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Form 144 Madrigal Pharmaceuticals For: 21 July By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares - Investing.com
Madrigal Pharmaceuticals (MDGL) insider files Form 144 for 2,500-share sale - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 22.65% Potential Upside - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (MDGL) Edition - Stock Traders Daily
Madrigal Expands Rezdiffra Patent Portfolio Into 2045 - MyChesCo
Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739 - Moomoo
Citizens raises Madrigal Pharmaceuticals price target on lower tax assumptions - Investing.com Nigeria
Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30 - Stock Titan
0.52%
0.07%
자본화:
|
볼륨(24시간):